AgriGenome Labs Pvt Ltd

Belkins
AgriGenome Labs (AgGenome) was started in 2013 as a division of SciGenom Labs and after successful incubation, it became an independent company in 2015 with facilities in Genome Valley, Hyderabad and "SmartCity Kochi"​, Cochin. Both the facilities are equipped with state-of-the-art instruments and provide genome sequencing, editing and bioinformatics services for Plant, Animal & Microbial projects of the industry as well as academic and government institutions. AgGenome genomics platforms include PacBio Sequel (first installation in Asia), Illumina sequencers, ABI 3730xl Sanger sequencers and more.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

ANIXA BIOSCIENCES TO FOCUS ON DEVELOPMENT AND EXPANSION OF ITS THERAPEUTICS AND VACCINE PORTFOLIO

Anixa Biosciences | July 03, 2020

news image

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it has strategically realigned its business focus and redirected resources to exclusively focus on the development of therapeutics and vaccines in high-need patient populations. As part of this realignment, the company has suspended development of the Cchek™ liquid biopsy technology.Going forward, Anixa's operations ...

Read More

MEDTECH

SEEGENE DEVELOPS WORLD'S FIRST COVID-19 DIAGNOSTIC VARIANT TEST CAPABLE OF IDENTIFYING MULTIPLE MUTANT VARIATIONS

Seegene | February 01, 2021

news image

South Korea's biotechnology firm Seegene (KQ096530) said Monday it built up the world's first COVID-19 diagnostic variation test, fit for screening COVID-19 and recognizing various mutant variations in a single reaction. Seegene's new variation test, the 'Allplex™ SARS-CoV-2 Variants I Assay,' can detect and separate virus variations, including those discovered to be more contagious and fatal. The new variation test identifies COVID-1...

Read More

CELL AND GENE THERAPY

BOSTON LABS AND GERMFREE LAUNCH MOBILE CELL AND GENE THERAPY (CGT) MANUFACTURING PLATFORM

BOSTON LABS | September 23, 2021

news image

Clinical logistics and life science manufacturing leaders Boston Labs and Germfree Laboratories Inc. announced their partnership to launch a new network of mobile CGT manufacturing facilities. The two companies are combining deep logistics, CGT manufacturing expertise and mobile cleanroom technology to deliver CGT point-of-care contract manufacturing services. The CGT mobile manufacturing platform will launch in Boston, MA in the fourth quarter of 2021 and will scale to a network ...

Read More

BLUEBIRD BIO LAUNCHES FIRST GENE THERAPY FOR BETA THALASSEMIA IN GERMANY

Labiotech | January 15, 2020

news image

The US company bluebird bio has launched the first gene therapy for the blood disorder transfusion-dependent beta thalassemia in the EU, with a hospital in Germany becoming its first qualified treatment center. Bluebird bio’s gene therapy, branded as Zynteglo, was given conditional market approval by the EU in June 2019. It was the first gene therapy approved to treat people over 12 years of age with all but the most severe form of transfusion-dependent beta thalassemia, a condition that n...

Read More

Anixa Biosciences | July 03, 2020

news image

ANIXA BIOSCIENCES TO FOCUS ON DEVELOPMENT AND EXPANSION OF ITS THERAPEUTICS AND VACCINE PORTFOLIO

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it has strategically realigned its business focus and redirected resources to exclusively focus on the development of therapeutics and vaccines in high-need patient populations. As part of this realignment, the company has suspended development of the Cchek™ liquid biopsy technology.Going forward, Anixa's operations ...

Read More

MEDTECH

Seegene | February 01, 2021

news image

SEEGENE DEVELOPS WORLD'S FIRST COVID-19 DIAGNOSTIC VARIANT TEST CAPABLE OF IDENTIFYING MULTIPLE MUTANT VARIATIONS

South Korea's biotechnology firm Seegene (KQ096530) said Monday it built up the world's first COVID-19 diagnostic variation test, fit for screening COVID-19 and recognizing various mutant variations in a single reaction. Seegene's new variation test, the 'Allplex™ SARS-CoV-2 Variants I Assay,' can detect and separate virus variations, including those discovered to be more contagious and fatal. The new variation test identifies COVID-1...

Read More

CELL AND GENE THERAPY

BOSTON LABS | September 23, 2021

news image

BOSTON LABS AND GERMFREE LAUNCH MOBILE CELL AND GENE THERAPY (CGT) MANUFACTURING PLATFORM

Clinical logistics and life science manufacturing leaders Boston Labs and Germfree Laboratories Inc. announced their partnership to launch a new network of mobile CGT manufacturing facilities. The two companies are combining deep logistics, CGT manufacturing expertise and mobile cleanroom technology to deliver CGT point-of-care contract manufacturing services. The CGT mobile manufacturing platform will launch in Boston, MA in the fourth quarter of 2021 and will scale to a network ...

Read More

Labiotech | January 15, 2020

news image

BLUEBIRD BIO LAUNCHES FIRST GENE THERAPY FOR BETA THALASSEMIA IN GERMANY

The US company bluebird bio has launched the first gene therapy for the blood disorder transfusion-dependent beta thalassemia in the EU, with a hospital in Germany becoming its first qualified treatment center. Bluebird bio’s gene therapy, branded as Zynteglo, was given conditional market approval by the EU in June 2019. It was the first gene therapy approved to treat people over 12 years of age with all but the most severe form of transfusion-dependent beta thalassemia, a condition that n...

Read More